Apolipoprotein A-V; a potent triglyceride reducer

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 15-21

  Nilsson, Stefan K ^a   Heeren, Joerg ^b   Olivecrona, Gunilla ^a   Merkel, Martin ^b,c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Apolipoprotein A V; Apolipoprotein A5; Heparan sulfate proteoglycans; Lipoprotein lipase; Lipoproteins; Plasma triglyceride metabolism

Indexed keywords

APOLIPOPROTEIN A5; CHYLOMICRON; LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

FAMILIAL HYPERLIPEMIA; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; LIVER CELL; MOLECULAR INTERACTION; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS A; CHYLOMICRONS; HEPATOCYTES; HUMANS; HYPERLIPOPROTEINEMIA TYPE IV; LIPOPROTEIN LIPASE; LIVER; MICE; TRIGLYCERIDES;

EID: 80055008025     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.019     Document Type: Review

References (99)

1. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (New York, N.Y) 2001, 294:169-173.
2. van der Vliet H.N., Sammels M.G., Leegwater A.C., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001, 276:44512-44520.
3. O'Brien P.J., Alborn W.E., Sloan J.H., et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005, 51:351-359.
4. Merkel M., Heeren J. Give me A5 for lipoprotein hydrolysis. J Clin Invest 2005, 115:2694-2696.
5. Alborn W.E., Johnson M.G., Prince M.J., Konrad R.J. Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum. Clin Chem 2006, 52:514-517.
6. Zhao S.P., Hu S., Li J., et al. Association of human serum apolipoprotein A5 with lipid profiles affected by gender. Clin Chim Acta 2007, 376:68-71.
7. Ishihara M., Kujiraoka T., Iwasaki T., et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 2005, 46:2015-2022.
8. Dallinga-Thie G.M., van Tol A., Hattori H., van Vark-van der Zee L.C., Jansen H., Sijbrands E.J. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 2006, 49(7):1505-1511.
9. Schaap F.G., Nierman M.C., Berbee J.F., et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res 2006, 47:2333-2339.
10. Vaessen S.F., Schaap F.G., Kuivenhoven J.A., et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 2006, 47:2064-2070.
11. Talmud P.J., Cooper J.A., Hattori H., Miller I.P., Miller G.J., Humphries S.E. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 2006, 49:2337-2340.
12. Henneman P., Schaap F.G., Havekes L.M., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 2007, 193:129-134.
13. Chan D.C., Watts G.F., Nguyen M.N., Barrett P.H. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol 2006, 26:590-596.
14. Merkel M., Loeffler B., Kluger M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005, 280:21553-21560.
15. Nelbach L., Shu X., Konrad R.J., Ryan R.O., Forte T.M. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J Lipid Res 2008, 49:572-580.
16. Schaap F.G., Rensen P.C., Voshol P.J., et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004, 279:27941-27947.
17. Vaessen S.F., Dallinga-Thie G.M., Ross C.J., et al. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. J Lipid Res 2009, 50:880-884.
18. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
19. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11:3031-3038.
20. Grallert H., Sedlmeier E.M., Huth C., et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007, 48:2614-2621.
21. Wright W.T., Young I.S., Nicholls D.P., Patterson C., Lyttle K., Graham C.A. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 2006, 185:353-360.
22. Lai C.Q., Demissie S., Cupples L.A., et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 2004, 45:2096-2105.
23. Zhao T., Zhao J. Association of the apolipoprotein A5 gene -1131 T>C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects. BMC Med Genet 2010, 11:120.
24. Johansen C.T., Wang J., Lanktree M.B., et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010, 42:684-687.
25. Kluger M., Heeren J., Merkel M. Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis 2008.
26. Laurila P.P., Naukkarinen J., Kristiansson K., et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vascr Biol 2010, 30:346-352.
27. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
28. Willer C.J., Sanna S., Jackson A.U., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169.
29. Hsu L.A., Ko Y.L., Chang C.J., et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 2006, 185:143-149.
30. Chien K.L., Hsu H.C., Chen Y.C., Su T.C., Lee Y.T., Chen M.F. Association between sequence variant of c.553 G>T in the apolipoprotein A5 gene and metabolic syndrome, insulin resistance, and carotid atherosclerosis. Transl Res 2009, 154:133-141.
31. Hsu L.A., Ko Y.L., Chang C.J., Teng M.S., Wu S., Hu C.F. Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. Clin Chem Lab Med 2008, 46:1714-1719.
32. Dallongeville J., Cottel D., Wagner A., et al. The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med Genet 2008, 9:84.
33. Corella D., Lai C.Q., Demissie S., et al. APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study. J Mol Med (Berlin, Germany) 2007, 85:119-128.
34. Aberle J., Evans D., Beil F.U., Seedorf U. A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin Genet 2005, 68:152-154.
35. van Dijk K.W., Rensen P.C., Voshol P.J., Havekes L.M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 2004, 15:239-246.
36. Pamir N., McMillen T.S., Li Y.I., Lai C.M., Wong H., LeBoeuf R.C. Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. Metab Clin Exp 2009, 58:560-567.
37. Mansouri R.M., Bauge E., Gervois P., et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res 2008, 103:450-453.
38. Coca-Prieto I., Kroupa O., Gonzalez-Santos P., et al. Childhood-onset chylomicronaemia with reduced plasma lipoprotein lipase activity and mass: identification of a novel GPIHBP1 mutation. J Intern Med 2011, [Epub ahead of print].
39. Olivecrona G., Ehrenborg E., Semb H., et al. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res 2010, 51:1535-1545.
40. Beigneux A.P., Franssen R., Bensadoun A., et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 2009, 29:956-962.
41. Wang J., Hegele R.A. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis 2007, 6:23.
42. Peterfy M., Ben-Zeev O., Mao H.Z., et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet 2007, 39:1483-1487.
43. Davies B.S., Beigneux A.P., Barnes R.H., et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab 2010, 12:42-52.
44. Priore Oliva C., Pisciotta L., Li Volti G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005, 25:411-417.
45. Marcais C., Verges B., Charriere S., et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005, 115:2862-2869.
46. Dorfmeister B., Zeng W.W., Dichlberger A., et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 2008, 28:1866-1871.
47. Priore Oliva C., Tarugi P., Calandra S., et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 2006, 188:215-217.
48. Okubo M., Ishihara M., Iwasaki T., et al. A novel APOA5 splicing mutation IVS2+1g>a in a Japanese chylomicronemia patient. Atherosclerosis 2009, 207:24-25.
49. Charriere S., Cugnet C., Guitard M., et al. Modulation of phenotypic expression of APOA5 Q97X and L242P mutations. Atherosclerosis 2009, 207:150-156.
50. Henneman P., Schaap F.G., Rensen P.C., van Dijk K.W., Smelt A.H. Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med 2008, 263:107-108.
51. Chang S.Y., Ko W.S., Kao J.T., et al. Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. Clin Infect Dis 2009, 48:832-835.
52. Vu-Dac N., Gervois P., Jakel H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003, 278:17982-17985.
53. Prieur X., Coste H., Rodriguez J.C. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003, 278:25468-25480.
54. Genoux A., Dehondt H., Helleboid-Chapman A., et al. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol 2005, 25:1186-1192.
55. Prieur X., Schaap F.G., Coste H., Rodriguez J.C. Hepatocyte nuclear factor-4alpha regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol Endocrinol (Baltimore, MD) 2005, 19:3107-3125.
56. Prieur X., Huby T., Coste H., Schaap F.G., Chapman M.J., Rodriguez J.C. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005, 280:27533-27543.
57. Jakel H., Nowak M., Moitrot E., et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004, 279:45462-45469.
58. Nowak M., Helleboid-Chapman A., Jakel H., et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 2005, 25:1537-1548.
59. Nowak M., Helleboid-Chapman A., Jakel H., et al. Glucose regulates the expression of the apolipoprotein A5 gene. J Mol Biol 2008, 380:789-798.
60. Song K.H. Orphan nuclear receptor Nur77 participates in human apolipoprotein A5 gene expression. Biochem Biophys Res Commun 2010, 392:63-66.
61. Beckstead J.A., Oda M.N., Martin D.D., et al. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochemistry 2003, 42:9416-9423.
62. Wong K., Beckstead J.A., Lee D., et al. The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture. Biochemistry 2008, 47:8768-8774.
63. Wong-Mauldin K., Raussens V., Forte T.M., Ryan R.O. Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants. J Biol Chem 2009, 284:33369-33376.
64. Beckstead J.A., Wong K., Gupta V., et al. The C terminus of apolipoprotein A-V modulates lipid-binding activity. J Biol Chem 2007, 282:15484-15489.
65. Sun G., Bi N., Li G., et al. Identification of lipid binding and lipoprotein lipase activation domains of human apoAV. Chem Phys Lipids 2006, 143:22-28.
66. Gin P., Beigneux A.P., Davies B., et al. Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim Biophys Acta 2007, 1771:1464-1468.
67. Gin P., Yin L., Davies B.S., et al. The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem 2008, 283:29554-29562.
68. Lookene A., Nielsen M.S., Gliemann J., Olivecrona G. Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins. Biochem Biophys Res Commun 2000, 271:15-21.
69. Nilsson S.K., Lookene A., Beckstead J.A., Gliemann J., Ryan R.O., Olivecrona G. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 2007, 46:3896-3904.
70. Lookene A., Beckstead J.A., Nilsson S., Olivecrona G., Ryan R.O. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 2005, 280:25383-25387.
71. Helleboid-Chapman A., Nowak M., Helleboid S., et al. Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine. Cell Physiol Biochem 2009, 24:451-460.
72. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl. 3):14-23.
73. Grosskopf I., Baroukh N., Lee S.J., et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 2005, 25:2573-2579.
74. Chiu K.C., Chiu Y.F., Boyadjian A.A., Fernando S., Kwan C., Chuang L.M. Impact of apolipoprotein A5 polymorphisms on insulin sensitivity and beta-cell function. Pancreas 2005, 30:328-332.
75. Weinberg R.B., Cook V.R., Beckstead J.A., et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003, 278:34438-34444.
76. Shu X., Ryan R.O., Forte T.M. Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment. J Lipid Res 2008, 49:1670-1676.
77. Shu X., Chan J., Ryan R.O., Forte T.M. Apolipoprotein A-V association with intracellular lipid droplets. J Lipid Res 2007, 48:1445-1450.
78. Kjolby M., Andersen O.M., Breiderhoff T., et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab 2010, 12:213-223.
79. Nilsson S.K., Christensen S., Raarup M.K., Ryan R.O., Nielsen M.S., Olivecrona G. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem 2008, 283:25920-25927.
80. Talmud P.J., Palmen J., Putt W., Lins L., Humphries S.E. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 2005, 280:28215-28220.
81. Forte T.M., Shu X., Ryan R.O. The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res 2009, 50(Suppl.):S150-S155.
82. Fruchart-Najib J., Bauge E., Niculescu L.S., et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004, 319:397-404.
83. Shu X., Nelbach L., Ryan R.O., Forte T.M. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation. Biochim Biophys Acta 2010, 1801:605-608.
84. Newberry E.P., Kennedy S.M., Xie Y., et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology 2008, 48:1097-1105.
85. Talmud P.J. Rare APOA5 mutations-clinical consequences, metabolic and functional effects: an ENID review. Atherosclerosis 2007, 194:287-292.
86. Young S.G., Davies B.S., Fong L.G., et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol 2007, 18:389-396.
87. Gerritsen G., van der Hoogt C.C., Schaap F.G., et al. ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. J Lipid Res 2008, 49:1048-1055.
88. Bartelt A., Bruns O.T., Reimer R., et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011, 17:200-205.
89. Shu X., Nelbach L., Weinstein M.M., et al. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol 2010, 30:2504-2509.
90. Baroukh N., Bauge E., Akiyama J., et al. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004, 24:1297-1302.
91. Qu S., Perdomo G., Su D., D'Souza F.M., Shachter N.S., Dong H.H. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res 2007, 48:1476-1487.
92. Beisiegel U., Weber W., Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991, 88:8342-8346.
93. Eisenberg S., Sehayek E., Olivecrona T., Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 1992, 90:2013-2021.
94. Stanford K.I., Bishop J.R., Foley E.M., et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest 2009, 119:3236-3245.
95. Taira K., Bujo H., Hirayama S., et al. LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol 2001, 21:1501-1506.
96. Ohwaki K., Bujo H., Jiang M., Yamazaki H., Schneider W.J., Saito Y. A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages. Arterioscler Thromb Vasc Biol 2007, 27:1050-1056.
97. Petersen C.M., Nielsen M.S., Nykjaer A., et al. Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 1997, 272:3599-3605.
98. Sandhu M.S., Waterworth D.M., Debenham S.L., et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet 2008, 371:483-491.
99. Linsel-Nitschke P., Heeren J., Aherrahrou Z., et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 2010, 208:183-189.